Literature DB >> 29764582

[Research advances in the role of aptamers in the diagnosis and targeted therapy of pediatric cancer].

Yi-Bin Zhang1, Yan-Peng Wang, Jing Liu.   

Abstract

Aptamers are single-stranded DNA or RNA which are isolated from synthesized random oligonucleotide library in vitro via systematic evolution of ligands by exponential enrichment (SELEX) and can bind to metal ions, small molecules, carbohydrates, lipids, proteins, and others targets with high affinity and specificity. Aptamers have the advantages of simple preparation, good thermal stability, and low immunogenicity and have great potential in the medical fields such as molecular imaging, biosensing, early diagnosis of diseases, and targeted therapy. Aptamer technology may be useful for early diagnosis and targeted therapy of pediatric cancer, and may avoid the side effects of conventional chemotherapy, such as growth and development disorders and long-term organ dysfunction. This article reviews the latest research advances in the selection and application of aptamers for pediatric cancer.

Entities:  

Mesh:

Year:  2018        PMID: 29764582      PMCID: PMC7389069     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  53 in total

1.  Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures.

Authors:  A D Ellington; J W Szostak
Journal:  Nature       Date:  1992-02-27       Impact factor: 49.962

2.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

3.  Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1.

Authors:  G Zhai; M Iskandar; K Barilla; P J Romaniuk
Journal:  Biochemistry       Date:  2001-02-20       Impact factor: 3.162

4.  Tenascin-C aptamers are generated using tumor cells and purified protein.

Authors:  B J Hicke; C Marion; Y F Chang; T Gould; C K Lynott; D Parma; P G Schmidt; S Warren
Journal:  J Biol Chem       Date:  2001-10-04       Impact factor: 5.157

Review 5.  Epidemiology of childhood cancer.

Authors:  Peter Kaatsch
Journal:  Cancer Treat Rev       Date:  2010-03-15       Impact factor: 12.111

6.  Midkine promotes neuroblastoma through Notch2 signaling.

Authors:  Satoshi Kishida; Ping Mu; Shin Miyakawa; Masatoshi Fujiwara; Tomoyuki Abe; Kazuma Sakamoto; Akira Onishi; Yoshikazu Nakamura; Kenji Kadomatsu
Journal:  Cancer Res       Date:  2012-12-14       Impact factor: 12.701

Review 7.  Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.

Authors:  Xin Li; Qinghe Zhao; Liyan Qiu
Journal:  J Control Release       Date:  2013-06-15       Impact factor: 9.776

8.  Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.

Authors:  Parag Parekh; Sanchit Kamble; Nianxi Zhao; Zihua Zeng; Bryce P Portier; Youli Zu
Journal:  Biomaterials       Date:  2013-08-19       Impact factor: 12.479

9.  Immuno Affinity SELEX for Simple, Rapid, and Cost-Effective Aptamer Enrichment and Identification against Aflatoxin B1.

Authors:  Keerthana Setlem; Bhairab Mondal; Shylaja Ramlal; Joseph Kingston
Journal:  Front Microbiol       Date:  2016-12-01       Impact factor: 5.640

10.  Molecular recognition of acute myeloid leukemia using aptamers.

Authors:  K Sefah; Z W Tang; D H Shangguan; H Chen; D Lopez-Colon; Y Li; P Parekh; J Martin; L Meng; J A Phillips; Y M Kim; W H Tan
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.